Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04044365 · ClinicalTrials.gov registry record

Pediatric cGVHD Symptom Scale

A clinical trial of Graft Vs Host Disease, sponsored by National Cancer Institute (NCI).

Recruiting
Registry status
420
Enrollment target
17
Study locations

NCT04044365 is a study of Graft Vs Host Disease that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 420 participants, above the 126-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (233% higher). The trial reports 17 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04044365, a study of Graft Vs Host Disease, is actively recruiting participants, sponsored by National Cancer Institute (NCI).

RECRUITING
Registry status
420 participants
Enrollment target
17
Study locations

Study Summary

Background: Some children/adolescents who have had a stem cell transplant live with chronic graft-versus-host-disease (cGVHD). cGVHD is a side effect of the transplant that can cause multiple bothersome symptoms and negatively affect a child/adolescent squality of daily life. The questionnaires that measure thesymptoms caused by cGVHD are designed for adults. Children/adolescents may not describe their symptoms in the same way. The goal of this research is to improve the way we measure how bothersome these symptoms are for children/adolescents living with cGVHD. Objective: To develop a questionnaire (The Pediatric cGHVD Symptom Scale) for children/adolescents living with cGVHD to identify the symptoms they are experiencing and describe how bothersome those symptoms are to them. An additional goal is to design a parent/guardian companion questionnaire that can be used to capture the symptom experiences of very young children who may not be able to complete a questionnaire. Eligibility: Children/adolescents ages 5-17 who are receiving treatment for cGVHD after a stem cell transplant, and their parent/guardian.. Design: This study consists of 2 projects. Children/adolescents with cGVHD and their parent/guardianparticipants will be grouped by the child/adolescent s age: 5-7, 8-12, and 13-17. In project 1, participants will complete an age-appropriate questionnaire about cGVHD symptoms. The questionnaire will ask about the child/adolescent s physical functioning and emotional well-being. The parent/guardian will out fill out a companion questionnaire online. The child/adolescent will then review their completed questionnaire during an interview with a researcher and will be asked whether the questions about their symptoms were difficult to understand. The parent/guardian and child/adolescent will then be interviewed together to further explore their responses to the questionnaires. Interviews will be done in person, by phone, and online. . Based on what is learn

Conditions Studied

Study Locations (17)

Maryland

  • Johns Hopkins Hospital (JHH) - Baltimore
  • National Institutes of Health Clinical Center - Bethesda

Texas

  • Texas Children's Hospital (TCH)-Baylor - Houston
  • The University of Texas MD Anderson Cancer Institute - Houston

Other

  • Hospital for Sick Children (SickKids) - Toronto
  • Children's & Women's Health Centre of British Columbia (CWHC of BC) - Vancouver BC

Arizona

  • Phoenix Children's Hospital - Phoenix

California

  • City of Hope - Duarte

Colorado

  • Children's Hospital Colorado (CHCO) - Aurora

District of Columbia

  • Children s National Medical Center (CNMC) - Washington D.C.

Georgia

  • Children's Healthcare of Atlanta - Egleston Hospital - Atlanta

Trial Details

FieldValue
Enrollment Target 420 participants
Start Date 2019-10-02
Est. Completion 2026-12-31

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT04044365

The ClinicalTrials.gov registry entry for NCT04044365 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 126-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (233% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Graft Vs Host Disease appearing as the primary indexed condition, and to 0 interventions.

NCT04044365 reports 17 study locations spanning 14 distinct geographic areas - top geographies include Maryland, Texas, Other.

Frequently Asked Questions

What is clinical trial NCT04044365 about?

NCT04044365 is a clinical study titled "Pediatric cGVHD Symptom Scale". Background: Some children/adolescents who have had a stem cell transplant live with chronic graft-versus-host-disease (cGVHD). cGVHD is a side effect of the transplant that can cause multiple bothersome symptoms and negatively affect a child/adolescent squality of daily life. The questionnaires tha...

What is the current status of trial NCT04044365?

This trial is currently recruiting. The enrollment target is 420 participants. The study started on 2019-10-02. Estimated completion is 2026-12-31.

What conditions does trial NCT04044365 study?

This clinical trial studies the following conditions: Graft Vs Host Disease.

Who is sponsoring clinical trial NCT04044365?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04044365 being conducted?

This trial has 17 study locations across Arizona, California, Colorado, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Graft Vs Host Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.